Clinical Trials
12
Active:0
Completed:2
Trial Phases
4 Phases
Early Phase 1:1
Phase 1:6
Phase 2:2
+1 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (10 trials with phase data)• Click on a phase to view related trials
Phase 1
6 (60.0%)Phase 2
2 (20.0%)Early Phase 1
1 (10.0%)Not Applicable
1 (10.0%)Inaticabtagene Autoleucel Injection in the Treatment of Autoimmune Hemolytic Anemia After Three or More Lines of Therapy
Not Applicable
Not yet recruiting
- Conditions
- AIHA - Cold Autoimmune Hemolytic Anemia
- Interventions
- Drug: CNCT19 cell injection
- First Posted Date
- 2025-07-29
- Last Posted Date
- 2025-08-12
- Lead Sponsor
- Juventas Cell Therapy Ltd.
- Target Recruit Count
- 12
- Registration Number
- NCT07091370
Inaticabtagene Autoleucel Injection in the Treatment of Refractory Systemic Lupus Erythematosus-related Immune Thrombocytopenia
Phase 1
Recruiting
- Conditions
- Autoimmune Thrombocytopenia
- Interventions
- First Posted Date
- 2025-02-14
- Last Posted Date
- 2025-08-07
- Lead Sponsor
- Juventas Cell Therapy Ltd.
- Target Recruit Count
- 12
- Registration Number
- NCT06826430
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
Long-term Observational Study of Patients Treated With Inaticabtagene Autoleucel Injection
Recruiting
- Conditions
- B-cell Tumors
- First Posted Date
- 2024-06-17
- Last Posted Date
- 2025-08-07
- Lead Sponsor
- Juventas Cell Therapy Ltd.
- Target Recruit Count
- 1000
- Registration Number
- NCT06461351
- Locations
- 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, Tianjin, China
Inaticabtagene Autoleucel Injection Treatment for Adult Relapsed or Refractory Acute Lymphocytic Leukemia
Not yet recruiting
- Conditions
- B-cell Acute Lymphoblastic Leukemia
- First Posted Date
- 2024-06-10
- Last Posted Date
- 2024-06-13
- Lead Sponsor
- Juventas Cell Therapy Ltd.
- Target Recruit Count
- 200
- Registration Number
- NCT06450067
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China
🇨🇳Peking University Third Hospital, Beijing, Beijing, China
🇨🇳Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong, China
Exploratory Clinical Study of CNCT19 Anti CD19 Cell Therapy in the Treatment of Refractory Autoimmune Diseases
Early Phase 1
Recruiting
- Conditions
- Lupus Erythematosus, Systemic
- Interventions
- First Posted Date
- 2024-03-18
- Last Posted Date
- 2025-02-10
- Lead Sponsor
- Juventas Cell Therapy Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT06316791
- Locations
- 🇨🇳
The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
- Prev
- 1
- 2
- 3
- Next
News
No news found